Register Before Friday, July 10 & Save Up To $580
AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September
Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations
GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)
Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches
ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2
GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation
Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy
September 15-17, 2026 | Boston, MA
